Skip to main content

Table 2 Maternal and neonatal outcomes according to the two screening strategies

From: Change in prevalence of gestational diabetes and obstetric complications when applying IADPSG screening criteria in a Belgian French speaking University Hospital. A retrospective cohort study

  Group A Group B OR (95%CI) p-value aOR (95% CI)a
Gestational Diabetes Mellitus n = 3496 n = 2555    
119 (3.4%) 416 (16.28%) 5.51 (4.46–6.81) < 0.001 5.53 (4.48–6.84)
Primary Cesarean section n = 3135 n = 2321    
386 (12.31%) 320 (13.79%) 1.13 (0.97–1.33) 0.109 1.07 (0.91–1.26)
Gestational hypertensive disorders n = 3496 n = 2555    
101 (2.89%) 73 (2.86%) 0.98 (0 .72–1.34) 0.942 0.93 (0.69–1.27)
Preterm birth n = 3496 n = 2555    
228 (6.52%) 162 (6.43%) 0.97 (0.78–1.19) 0.777 0.97 (0 .79–1.2)
5′ Apgar score < 7 n = 3489 n = 2547    
76 (2.18%) 56 (2.2%) 1.009 (0.71–1.43) 0.957 0.98 (0.69–1.40)
Transfer to NICU n = 3404 n = 2547    
277 (8.14%) 208 (8.17%) 1.003 (0.83–1.21) 0.968 0.97 (0.81–1.18)
Neonatal hypoglycaemia n = 392 n = 438    
65 (16.58%) 90 (20.55%) 1.3 (0.91–1.85) 0.144 1.37 (0.96–1.97)
Shoulder dystocia n = 3489 n = 2547    
64 (1.83%) 56 (2.20%) 1.2 (0.83–1.72) 0.317 1.19 (0.83–1.72)
LGA n = 3496 n = 2555    
433 (12.39%) 276 (10.81%) 0.85 (0.73–1.006) 0.059 0.87 (0.74–1.03)
Macrosomia n = 3496 n = 2555    
319 (9.12%) 198 (7.75%) 0.83 (0 .69–1.006) 0.059 0.85 (0.71–1.03)
  1. aadjusted for nationality and parity